Research & Development



  “去病說了,不告訴閑雜人等。”   紅袖蹲下去卸掉雲瑯的鞋子,給他換上柔軟的拖鞋,然後抓著雲瑯的手站起來,笑吟吟的道︰“從今天起,妾身便是雲氏婦人了……”2345福彩3d彩票走势图   “當柴燒了。”2彩票网   在戰時權力很大,戰事結束之後,職位自動消除,是一個真正的沒有後患的官職……你要好好的為國征戰,報效國家,將匈奴清除干淨。   條陳就在他的懷里,隋越用手捂著胸口,很怕條陳自己跳出來,再次對雲瑯道︰“君侯果真沒有好人才了?”360买彩票   “妾身的孩子將來不會受人欺負吧?”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo